MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/cid/ciae338

Медицинская библиотека · Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024

Clinical Subphenotypes of Staphylococcus aureus Bacteremia.

Swets Maaike C, Bakk Zsuzsa, Westgeest Annette C, Berry Karla, Cooper George, Sim Wynne, Lee Rui Shian, Gan Tze Yi, Donlon William, Besu Antonia, Heppenstall Emily, Tysall Luke, Dewar Simon, de Boer Mark, Fowler Vance G, Dockrell David H, Thwaites Guy E, Pujol Miquel, Pallarès Natàlia, Tebé Cristian, Carratalà Jordi, Szubert Alexander, Groeneveld Geert H, Russell Clark D

СтатьяНаблюдательное исследованиеПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Staphylococcus aureus bacteremia (SAB) is a clinically heterogeneous disease. The ability to identify subgroups of patients with shared traits (subphenotypes) is an unmet need to allow patient stratification for clinical management and research. We aimed to test the hypothesis that clinically relevant subphenotypes can be reproducibly identified among patients with SAB.

METHODS

We studied 3 cohorts of adults with monomicrobial SAB: a UK retrospective observational study (Edinburgh cohort, n = 458), the UK ARREST trial (n = 758), and the Spanish SAFO trial (n = 214). Latent class analysis was used to identify subphenotypes using routinely collected clinical data without considering outcomes. Mortality and microbiologic outcomes were then compared between subphenotypes.

RESULTS

Included patients had predominantly methicillin-susceptible SAB (1366 of 1430, 95.5%). We identified 5 distinct, reproducible clinical subphenotypes: (A) SAB associated with older age and comorbidity, (B) nosocomial intravenous catheter-associated SAB in younger people without comorbidity, (C) community-acquired metastatic SAB, (D) SAB associated with chronic kidney disease, and (E) SAB associated with injection drug use. Survival and microbiologic outcomes differed between the subphenotypes. Mortality was highest in subphenotype A and lowest in subphenotypes B and E. Microbiologic outcomes were worse in subphenotype C. In a secondary analysis of the ARREST trial, adjunctive rifampicin was associated with increased mortality in subphenotype B and improved microbiologic outcomes in subphenotype C.

CONCLUSIONS

We have identified reproducible and clinically relevant subphenotypes within SAB and provide proof of principle of differential treatment effects. Through clinical trial enrichment and patient stratification, these subphenotypes could contribute to a personalized medicine approach to SAB.

Для цитирования: Swets Maaike C, Bakk Zsuzsa, Westgeest Annette C, Berry Karla, Cooper George, Sim Wynne, Lee Rui Shian, Gan Tze Yi, Donlon William, Besu Antonia, Heppenstall Emily, Tysall Luke, Dewar Simon, de Boer Mark, Fowler Vance G, Dockrell David H, Thwaites Guy E, Pujol Miquel, Pallarès Natàlia, Tebé Cristian, Carratalà Jordi, Szubert Alexander, Groeneveld Geert H, Russell Clark D. Clinical Subphenotypes of Staphylococcus aureus Bacteremia.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2024. DOI: 10.1093/cid/ciae338.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.